Surgery Partners (SGRY) Stock Price, News & Analysis

Company Overview

Surgery Partners, Inc. (NASDAQ: SGRY), founded in 2010 and headquartered in Nashville, Tennessee, is a leading provider of surgical healthcare services in the United States. The company offers a comprehensive platform that supports the development, acquisition and management of ambulatory surgery centers, surgical hospitals and diagnostic and imaging facilities. Surgery Partners focuses on delivering high-quality, cost-effective care by combining clinical expertise with streamlined operations.

The company partners closely with physicians across a wide range of specialties, including orthopedics, ophthalmology, gastroenterology, pain management and urology. Through these partnerships, Surgery Partners assists in site selection, facility design and construction, regulatory compliance and ongoing operational management. Its vertically integrated model encompasses not only surgical and imaging services but also revenue cycle management and supply chain coordination, helping physician practices and hospital systems optimize performance.

Since its inception, Surgery Partners has grown through a strategic mix of de novo development and targeted acquisitions, expanding its presence in both metropolitan and mid‐sized markets. Today, the company operates a network of ambulatory surgery centers, surgical hospitals and diagnostic facilities spanning more than two dozen states. This geographic diversification allows Surgery Partners to serve a broad patient base while maintaining strong relationships with local physician groups and health systems.

Under the leadership of President and Chief Executive Officer Tony Strange and a seasoned executive team, Surgery Partners emphasizes clinical quality, patient safety and operational excellence. The company leverages standardized protocols and data-driven performance metrics to drive continuous improvement, and it works with accrediting bodies and payers to support value‐based care initiatives. With a focus on sustainable growth and enhanced patient outcomes, Surgery Partners aims to be a trusted partner for physicians, health systems and communities nationwide.

Key Stats

• Today's Range: $21.93 to $22.26
• 50-Day Range: $19.30 to $23.94
• 52-Week Range: $18.87 to $33.97
• Volume: 793,153 shs
• Average Volume: 1.21 million shs
• Market Capitalization: $2.82 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.56
• Consensus Rating: Moderate Buy

Surgery Partners Stock Analysis - MarketRank™

Surgery Partners scored higher than 50% of companies evaluated by MarketBeat, and ranked 658th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Surgery Partners has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Surgery Partners has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 20.90%

Earnings Growth

Earnings for Surgery Partners are expected to grow by 20.90% in the coming year, from $0.67 to $0.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Surgery Partners is -14.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Surgery Partners is -14.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Surgery Partners has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.07% of the float of Surgery Partners has been sold short.

Short Interest Ratio / Days to Cover

Surgery Partners has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Surgery Partners has recently increased by 21.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Surgery Partners does not currently pay a dividend.

Dividend Growth

Surgery Partners does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.07% of the float of Surgery Partners has been sold short.

Short Interest Ratio / Days to Cover

Surgery Partners has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Surgery Partners has recently increased by 21.47%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.62

News Sentiment

Surgery Partners has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Surgery Partners this week, compared to 5 articles on an average week.

Search Interest

1 people have searched for SGRY on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Surgery Partners insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.30% of the stock of Surgery Partners is held by insiders.

SGRY Stock Analysis - Frequently Asked Questions

How have SGRY shares performed this year?

Surgery Partners' stock was trading at $21.17 at the beginning of 2025. Since then, SGRY stock has increased by 4.1% and is now trading at $22.04.

How were Surgery Partners' earnings last quarter?

Surgery Partners, Inc. (NASDAQ:SGRY) issued its quarterly earnings results on Monday, May, 12th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.04. The firm's quarterly revenue was up 8.2% on a year-over-year basis.
Read the conference call transcript.

Who are Surgery Partners' major shareholders?

Surgery Partners' top institutional investors include E. Ohman J or Asset Management AB (0.75%) and Wesbanco Bank Inc. (0.09%). Insiders that own company stock include Andrew T Kaplan, Jason Eric Evans, David T Doherty, Jennifer Baldock, Wayne S Deveydt, Harrison R Bane, Bradley R Owens, Marissa Brittenham, William Trenton Webb, Brent Turner, Laura L Brocklehurst and Danielle Burkhalter.
View institutional ownership trends.

How do I buy shares of Surgery Partners?

Shares of SGRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Surgery Partners own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Surgery Partners investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:SGRY
• CIK: 1638833
• Web: www.surgerypartners.com
• Phone: (615) 234-5900
• Fax: 615-234-5998
• Employees: 15,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Surgery Partners: $33.56
• High Price Target: $43.00
• Low Price Target: $24.00
• Potential Upside/Downside: +52.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 32.90
• P/E Growth: N/A
• Net Income: -$168.10 million
• Net Margins: -6.10%
• Pretax Margin: 3.72%
• Return on Equity: 2.41%
• Return on Assets: 0.99%

Debt

• Debt-to-Equity Ratio: 1.09
• Current Ratio: 1.89
• Quick Ratio: 1.73

Sales & Book Value

• Annual Sales: $3.11 billion
• Price / Sales: 0.91
• Cash Flow: $1.87 per share
• Price / Cash Flow: 11.77
• Book Value: $25.15 per share
• Price / Book: 0.88

Miscellaneous

• Outstanding Shares: 128,160,000
• Free Float: 125,212,000
• Market Cap: $2.82 billion
• Optionable: Optionable
• Beta: 1.90